We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

GSK, Zofran Users Bicker Over Scope Of Patient Discovery

Law360, Boston (April 25, 2018, 7:56 PM EDT) -- Counsel for GlaxoSmithKline and families who claim its anti-nausea medication Zofran caused various birth defects argued in Boston federal court Wednesday over how many patients should be targeted for individual discovery in the multidistrict product liability litigation.

The pharmaceutical giant proposed questioning 240 people, or more than half of the roughly 425 patients whose cases have been consolidated in Massachusetts, while the families said subjecting eight people to discovery should be more than enough to identify potential bellwether cases. The families claim GSK knowingly and wrongfully asked prescribers...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In Re: Zofran (Ondansetron)Products Liability Litigation


Case Number

1:15-md-02657

Court

Massachusetts

Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Judge

F. Dennis Saylor, IV

Date Filed

October 13, 2015

Law Firms

Companies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.